NCT03438396 2023-07-25A Trial of Tisotumab Vedotin in Cervical CancerSeagen Inc.Phase 2 Completed102 enrolled 20 charts 1 FDA
NCT03657043 2023-05-06A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)Seagen Inc.Phase 2 Completed98 enrolled 30 charts
NCT03245736 2021-11-04Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.Seagen Inc.Phase 2 Completed5 enrolled 8 charts